FucT-IV Antibodies

Santa Cruz Biotechnology features a diverse variety of FucT-IV Antibodies for advanced research in the field of glycosylation. FucT-IV Antibodies are validated for multiple techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). FucT-IV, or fucosyltransferase IV, plays a critical role in the biosynthesis of fucosylated glycans, which are essential for cell-cell interactions, immune response modulation, and tumor progression. Understanding FucT-IV function is vital for elucidating its involvement in various pathological conditions, including cancer metastasis and inflammatory diseases. The study of FucT-IV and its associated pathways can provide significant insights into therapeutic targets for disease intervention. Researchers worldwide utilize FucT-IV monoclonal antibodies to explore cellular mechanisms and potential therapeutic applications. Advanced research techniques incorporating FucT-IV monoclonal antibodies help uncover new pathways in disease progression and treatment. Santa Cruz Biotechnology monoclonal antibodies support researchers in making meaningful contributions to scientific knowledge and therapeutic development.